BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3429376)

  • 1. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis.
    Kaatz GW; Barriere SL; Schaberg DR; Fekety R
    J Antimicrob Chemother; 1987 Nov; 20(5):753-8. PubMed ID: 3429376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1989 Apr; 33(4):519-21. PubMed ID: 2499251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Barriere SL; Schaberg DR; Fekety R
    Antimicrob Agents Chemother; 1987 Apr; 31(4):527-30. PubMed ID: 3649202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Lamp KC; Bailey EM; Rybak MJ
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.
    Fernandez-Guerrero M; Rouse M; Henry N; Wilson W
    Antimicrob Agents Chemother; 1988 May; 32(5):747-51. PubMed ID: 3164989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ciprofloxacin in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis caused by a cloxacillin-tolerant strain and its non-tolerant variant.
    Voorn GP; Thompson J; Goessens WH; Schmal-Bauer WC; Broeders PH; Michel MF
    J Antimicrob Chemother; 1994 Apr; 33(4):785-94. PubMed ID: 8056697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1547-50. PubMed ID: 1929325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
    Chambers HF; Xiang Q; Liu ; Chow LL; Hackbarth C
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2742-6. PubMed ID: 10543757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination.
    Perronne CM; Malinverni R; Glauser MP
    Antimicrob Agents Chemother; 1987 Apr; 31(4):539-43. PubMed ID: 3606060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
    Kim YS; Liu Q; Chow LL; Chambers HF; Täuber MG
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1184-7. PubMed ID: 2802547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1990 Feb; 34(2):257-60. PubMed ID: 2327773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
    Chambers HF
    Antimicrob Agents Chemother; 2005 Mar; 49(3):884-8. PubMed ID: 15728879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.
    Carpenter TC; Hackbarth CJ; Chambers HF; Sande MA
    Antimicrob Agents Chemother; 1986 Sep; 30(3):382-4. PubMed ID: 3640590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
    Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis.
    Fernández Guerrero ML; de Górgolas M
    J Antimicrob Chemother; 2006 Nov; 58(5):1066-9. PubMed ID: 16931540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.